Entropy Neurodynamics

Entropy Neurodynamics Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 69.94 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 145.71 % — a change of -52.00% (lower).

Cash Conversion

69.94 %

YoY

-52.00%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Entropy Neurodynamics is 2026 69.94 % . Cash Conversion Rate (OCF/Net Income) of Entropy Neurodynamics was 2025 145.71 % . It decreases by -52.00% lower compared to the previous year.

The Entropy Neurodynamics Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
95.69 AUD
Jan 1, 2020
127.27 AUD
Jan 1, 2021
93.13 AUD
Jan 1, 2022
85.21 AUD
Jan 1, 2023
56.46 AUD
Jan 1, 2024
97.68 AUD
Jan 1, 2025
145.71 AUD
Jan 1, 2026
69.94 AUD
The Entropy Neurodynamics Cash Conversion history
YEARCash ConversionYoY
69.94 %-52.00%
145.71 %+49.17%
97.68 %+73.01%
56.46 %-33.74%
85.21 %-8.50%
93.13 %-26.82%
127.27 %+33.00%
95.69 %+77.87%
53.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Cash Conversion Rate (OCF/Net Income) of Entropy Neurodynamics is 69.94 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Entropy Neurodynamics changed from 145.71 % to 69.94 %, representing a -52.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics